ClinicalTrials.Veeva

Menu
S

Springfield Clinic | Clinical Research Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cisplatin
Paclitaxel
Carboplatin
Nivolumab
Atezolizumab
Pembrolizumab
Lenalidomide
Docetaxel
Dexamethasone
Gemcitabine Hydrochloride

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 352 total trials

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administere...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Drug: Atezolizumab
Drug: Placebo
Locations recently updated

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling
Small Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Venetoclax
Drug: Ibrutinib
Locations recently updated

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor D...

Enrolling
Stage III Colon Cancer
Drug: mFOLFOX6 3-6 month
Device: Signatera test

This is a non-blinded, prospective, multi-center, single arm longitudinal cohort study (patient serving as their own control), to evaluate the effect...

Enrolling
Diabetes
Device: Blood glucose meter
Device: Eversense CGM System

This randomized phase III trial compares ixazomib citrate, lenalidomide, dexamethasone and zoledronic acid with zoledronic acid alone to see how well...

Active, not recruiting
Solitary Osseous Plasmacytoma
Drug: dexamethasone
Drug: lenalidomide

The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the...

Active, not recruiting
Rheumatoid Arthritis
Drug: Filgotinib
Drug: Placebo to match filgotinib

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting
Psoriasis
Drug: BMS-986165

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
Wet AMD
Genetic: RGX-314
Biological: Ranibizumab (LUCENTIS®)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Genetic: RGX-314 Dose 2
Biological: Aflibercept (EYLEA®)

This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to se...

Active, not recruiting
Multiple Myeloma in Relapse
Drug: ixazomib
Drug: pomalidomide

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment o...

Enrolling
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Biological: Pembrolizumab
Biological: Ramucirumab

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and...

Active, not recruiting
Colorectal Neoplasms
Drug: Eflornithine placebo & sulindac placebo
Drug: Eflornithine plus sulindac

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen depriva...

Active, not recruiting
Prostate Cancer
Drug: Bicalutamide
Drug: TAK-700

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenan...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab/rHuPH20

Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.

Enrolling
Primary Biliary Cholangitis
Drug: K-808 (Dose A)
Drug: Placebo

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in pa...

Enrolling
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Biological: Trastuzumab Emtansine
Other: Quality-of-Life Assessment

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cel...

Enrolling
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Procedure: Magnetic Resonance Imaging
Biological: Ramucirumab

Trial sponsors

National Cancer Institute (NCI) logo
SWOG Cancer Research Network logo
Alliance for Clinical Trials in Oncology logo
ECOG-ACRIN Cancer Research Group logo
NRG Oncology logo
AbbVie logo
Wake Forest University (WFU) logo
Pfizer logo
G
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems